Limits...
Role of Bcl-2 -938 C > A polymorphism in susceptibility and prognosis of cancer: a meta-analysis

View Article: PubMed Central - PubMed

ABSTRACT

The association between B-cell lymphoma 2 (Bcl-2) polymorphism and cancer is under debate and remains elusive. This meta-analysis was performed to evaluate the relationships of Bcl-2 -938 C>A polymorphism (rs2279115) with susceptibility and prognosis of cancer. Odds ratios (ORs) were used to measure the association between Bcl-2 polymorphisms and cancer risk. Hazard ratios (HRs) were used to measure the association between Bcl-2 polymorphisms and cancer prognosis. On the basis of 26 studies about Bcl-2 -938C>A polymorphism and cancer, we found Bcl-2 -938 C>A polymorphism was significantly associated with increased cancer risk in dominant model (OR = 1.12, 95%CI: 1.00–1.25, P = 0.04), recessive model (OR = 1.38, 95%CI: 1.11–1.71, P = 0.004), allelic model (OR = 1.15, 95%CI: 1.04–1.28, P = 0.007) and homozygote comparison(OR = 1.44, 95%CI: 1.11–1.87, P = 0.006). Furthermore, Bcl-2 -938 C>A polymorphism was significantly associated with increased cancer risk in Asians but not in Caucasians. Moreover, Bcl-2 -938 C>A polymorphism was not significantly associated with the prognosis of cancer (AA vs CA: OR = 0.99, 95%CI: 0.77–1.27, P = 0.93; AA vs CC: OR = 0.92, 95%CI: 0.65–1.30, P = 0.63; AC vs CC: OR = 0.94, 95%CI: 0.80–1.11, P = 0.48; CC vs AA+CA: OR = 1.21, 95%CI: 0.69–2.13, P = 0.50; AA vs CC+CA: OR = 0.99, 95%CI: 0.48–2.04, P = 0.97). Studies with larger samples and gene-environment interactions are needed to validate our findings.

No MeSH data available.


Related in: MedlinePlus

Forest plot of Bcl-2 -938 C>A polymorphism and cancer risk in dominant model.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5384243&req=5

f2: Forest plot of Bcl-2 -938 C>A polymorphism and cancer risk in dominant model.

Mentions: Overall, twelve studies enrolling 5515 cases and 6290 controls were included in our meta-analysis. A statistical significant association between Bcl-2 -938 C>A polymorphism and cancer susceptibility was found under the dominant model (OR = 1.12, 95%CI: 1.00-1.25, P = 0.04) (Fig. 2), recessive model (OR = 1.38, 95%CI: 1.11–1.71, P = 0.004) (Fig. 3), allelic model (OR = 1.15, 95%CI: 1.04–1.28, P = 0.007) (Fig. 4) and homozygote comparison(OR = 1.44, 95%CI: 1.11–1.87, P = 0.006) (Fig. 5). And no significant association was found under the heterozygote comparison (OR = 1.05, 95%CI: 0.97–1.14, P = 0.22) (Supplementary Figure S1). Bcl-2 -938 C>A polymorphism was significantly associated with increased cancer risk in Asians under five genetic models (dominant model: OR = 1.19, 95%CI: 1.08–1.31, P = 0.0005; recessive model: OR = 1.83, 95%CI: 1.28–2.62, P = 0.0009; allelic model: OR = 1.28, 95%CI:1.12–1.47, P = 0.0003; homozygote comparison: OR = 1.96, 95%CI: 1.35–2.85, p = 0.006; heterozygote comparison: OR = 1.11, 95%CI: 1.11–1.23, P = 0.04). However, Bcl-2 -938 C>A polymorphism was not significantly associated with cancer risk in Caucasians (dominant model: OR = 0.96, 95%CI: 0.79–1.16,P = 0.65; recessive model: OR = 1.04, 95%CI: 0.89–1.21, P = 0.82; allelic model: OR = 1.00, 95%CI: 0.89–1.12, P = 0.97; homozygote comparison: OR = 0.98, 95%CI:0.75–1.29, P = 0.91; heterozygote comparison: OR = 0.94, 95%CI:0.80–1.11, P = 0.48). Supplementary Table S3 displays the results of overall and subgroup analysis.


Role of Bcl-2 -938 C > A polymorphism in susceptibility and prognosis of cancer: a meta-analysis
Forest plot of Bcl-2 -938 C>A polymorphism and cancer risk in dominant model.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5384243&req=5

f2: Forest plot of Bcl-2 -938 C>A polymorphism and cancer risk in dominant model.
Mentions: Overall, twelve studies enrolling 5515 cases and 6290 controls were included in our meta-analysis. A statistical significant association between Bcl-2 -938 C>A polymorphism and cancer susceptibility was found under the dominant model (OR = 1.12, 95%CI: 1.00-1.25, P = 0.04) (Fig. 2), recessive model (OR = 1.38, 95%CI: 1.11–1.71, P = 0.004) (Fig. 3), allelic model (OR = 1.15, 95%CI: 1.04–1.28, P = 0.007) (Fig. 4) and homozygote comparison(OR = 1.44, 95%CI: 1.11–1.87, P = 0.006) (Fig. 5). And no significant association was found under the heterozygote comparison (OR = 1.05, 95%CI: 0.97–1.14, P = 0.22) (Supplementary Figure S1). Bcl-2 -938 C>A polymorphism was significantly associated with increased cancer risk in Asians under five genetic models (dominant model: OR = 1.19, 95%CI: 1.08–1.31, P = 0.0005; recessive model: OR = 1.83, 95%CI: 1.28–2.62, P = 0.0009; allelic model: OR = 1.28, 95%CI:1.12–1.47, P = 0.0003; homozygote comparison: OR = 1.96, 95%CI: 1.35–2.85, p = 0.006; heterozygote comparison: OR = 1.11, 95%CI: 1.11–1.23, P = 0.04). However, Bcl-2 -938 C>A polymorphism was not significantly associated with cancer risk in Caucasians (dominant model: OR = 0.96, 95%CI: 0.79–1.16,P = 0.65; recessive model: OR = 1.04, 95%CI: 0.89–1.21, P = 0.82; allelic model: OR = 1.00, 95%CI: 0.89–1.12, P = 0.97; homozygote comparison: OR = 0.98, 95%CI:0.75–1.29, P = 0.91; heterozygote comparison: OR = 0.94, 95%CI:0.80–1.11, P = 0.48). Supplementary Table S3 displays the results of overall and subgroup analysis.

View Article: PubMed Central - PubMed

ABSTRACT

The association between B-cell lymphoma 2 (Bcl-2) polymorphism and cancer is under debate and remains elusive. This meta-analysis was performed to evaluate the relationships of Bcl-2 -938 C>A polymorphism (rs2279115) with susceptibility and prognosis of cancer. Odds ratios (ORs) were used to measure the association between Bcl-2 polymorphisms and cancer risk. Hazard ratios (HRs) were used to measure the association between Bcl-2 polymorphisms and cancer prognosis. On the basis of 26 studies about Bcl-2 -938C>A polymorphism and cancer, we found Bcl-2 -938 C>A polymorphism was significantly associated with increased cancer risk in dominant model (OR = 1.12, 95%CI: 1.00–1.25, P = 0.04), recessive model (OR = 1.38, 95%CI: 1.11–1.71, P = 0.004), allelic model (OR = 1.15, 95%CI: 1.04–1.28, P = 0.007) and homozygote comparison(OR = 1.44, 95%CI: 1.11–1.87, P = 0.006). Furthermore, Bcl-2 -938 C>A polymorphism was significantly associated with increased cancer risk in Asians but not in Caucasians. Moreover, Bcl-2 -938 C>A polymorphism was not significantly associated with the prognosis of cancer (AA vs CA: OR = 0.99, 95%CI: 0.77–1.27, P = 0.93; AA vs CC: OR = 0.92, 95%CI: 0.65–1.30, P = 0.63; AC vs CC: OR = 0.94, 95%CI: 0.80–1.11, P = 0.48; CC vs AA+CA: OR = 1.21, 95%CI: 0.69–2.13, P = 0.50; AA vs CC+CA: OR = 0.99, 95%CI: 0.48–2.04, P = 0.97). Studies with larger samples and gene-environment interactions are needed to validate our findings.

No MeSH data available.


Related in: MedlinePlus